IBD: Optimized Infliximab Monotherapy vs Combination Therapy IBD: Optimized Infliximab Monotherapy vs Combination Therapy
This study compared the clinical efficacy and cost of two different IBD treatment strategies for the introduction of infliximab: 6-12 months in combination with azathioprine versus optimized monotherapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news
Infliximab Biosimilar CT-P13 Noninferior in Active Crohn's Disease Infliximab Biosimilar CT-P13 Noninferior in Active Crohn's Disease
The infliximab biosimilar CT-P13 is noninferior to infliximab for treating patients with active Crohn ' s disease, according to a randomized controlled trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 11, 2019 Category: Orthopaedics Tags: Gastroenterology News Source Type: news
Infliximab and Risk of Serious Infection in Psoriasis Infliximab and Risk of Serious Infection in Psoriasis
Does infliximab increase the risk of serious infection as compared to nonbiologic systemic therapies in patients with psoriasis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Predicting Relapse Following Infliximab De-escalation in IBD Predicting Relapse Following Infliximab De-escalation in IBD
This study aimed to assess the rate of relapse following infliximab de-escalation in IBD patients in remission. How might infliximab trough level impact relapse?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Laparoscopic Surgery for Crohn's More Cost-Effective Than Infliximab (CME/CE)
(MedPage Today) -- More QALYs gained, 1-year health-related costs less (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 10, 2019 Category: Surgery Source Type: news
Laparoscopic Resection in Crohn's More Cost-Effective Than Infliximab
(MedPage Today) -- More QALYs gained and 1-year health costs were $10,000 less in European study (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 5, 2019 Category: Gastroenterology Source Type: news
Switching Between Reference and Biosimilar Infliximab Switching Between Reference and Biosimilar Infliximab
Is switching between infliximab and its biosimilar safe and efficacious in patients with inflammatory disorders?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Biosimilar to Infliximab Switch Yields Similar IBD Outcomes (CME/CE)
(MedPage Today) -- No significant changes in clinical remission, and no new safety signals (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 16, 2019 Category: Rheumatology Source Type: news
Not Just Acid Reflux: The Need to Think Worst First
Discussion
Heart disease is the leading cause of death in the United States.1 This year, 720,000 Americans will have a new coronary event—defined as first hospitalized myocardial infarction (MI) or coronary heart disease death—and around 335,000 will have a recurrent event. Approximately 35% of people who experience a coronary event in a given year and around 14% of patients who have an acute coronary syndrome will die from it.1 Roughly 60% of patients with an acute coronary syndrome are transported to the emergency department via ambulance.2–4.
Up to one-third of patients experiencing an MI may not complain of chest...
Source: JEMS Special Topics - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news
Not Just Acid Reflux: The Need to Think Worst First
A previously healthy, well-appearing 42-year-old female living in a modern, high-rise apartment in downtown Los Angeles calls 9-1-1 at 5:30 am complaining of worsening of a burning, epigastric pain she had been experiencing for the last three days. She reports associated nausea and non-bloody, non-bilious vomiting, and that she couldn’t manage to get comfortable in bed until she finally decided to call for help at daybreak.
During her 9-1-1 call, she reports “pain, like heartburn, that just woke me up again and I had to throw up, … and then I was sweating so much.” Using the Los Angeles Tiered Dispatch System, the ...
Source: JEMS Patient Care - January 13, 2019 Category: Emergency Medicine Authors: Stephen Sanko, MD, FACEP Tags: Exclusive Articles Cardiac & Resuscitation Source Type: news
Switch From Biosimilar to Originator Infliximab Safe in IBD
(MedPage Today) -- No significant changes in clinical remission, trough levels, or antidrug antibody status (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 11, 2019 Category: Gastroenterology Source Type: news
Infliximab & quot;most cost-effective option & quot; in Crohn's disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2019 Category: Drugs & Pharmacology Source Type: news
Infection Risk Lower With Orencia vs Anti-TNF
(MedPage Today) -- Increased risk for hospitalized infection with TNF inhibitors was driven largely by infliximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 26, 2018 Category: Primary Care Source Type: news
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab).
"At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging our deep expertise and heritage in biologics to produce a portfolio of biosimilars to serve pati...
Source: Amgen News Release - December 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE®... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 17, 2018 Category: Drugs & Pharmacology Source Type: news
